{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:15:24Z","timestamp":1791512124423,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National MS Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS041435"],"award-info":[{"award-number":["R01 NS041435"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.neurot.2024.e00379","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T17:00:17Z","timestamp":1716656417000},"page":"e00379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacological modulation of inflammatory oligodendrocyte progenitor cells using three multiple sclerosis disease modifying therapies in vitro"],"prefix":"10.1016","volume":"21","author":[{"given":"Larissa","family":"Jank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley B.","family":"Catenacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Minney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Galleguillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2024.e00379_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2024.e00379_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102194","article-title":"Breaking the barriers to remyelination in multiple sclerosis","volume":"63","author":"Gharagozloo","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.neurot.2024.e00379_bib3","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1093\/brain\/awab106","article-title":"BMP receptor blockade overcomes extrinsic inhibition of remyelination and restores neurovascular homeostasis","volume":"144","author":"Petersen","year":"2021","journal-title":"Brain [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/glia.20232","article-title":"Interferon-g inhibits cell cycle exit in differentiating oligodendrocyte progenitor cells","volume":"52","author":"Chew","year":"2005","journal-title":"Glia [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib5","first-page":"1","article-title":"Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination","volume":"10","author":"Kirby","year":"2019","journal-title":"Nat Commun [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib6","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41591-018-0236-y","article-title":"Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis","volume":"24","author":"Falc\u00e3o","year":"2018","journal-title":"Nat Med [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib7","first-page":"1","article-title":"A\u00a0lymphocyte\u2013microglia\u2013astrocyte axis in chronic active multiple sclerosis","author":"Absinta","year":"2021","journal-title":"Nature [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41586-019-1404-z","article-title":"Neuronal vulnerability and multilineage diversity in multiple sclerosis Molecular changes associated with MS pathogenesis","volume":"573","author":"Schirmer","year":"2019","journal-title":"Nature [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib9","article-title":"MHC class II and MHC class II reporter mice enable analysis of immune oligodendroglia in mouse models of multiple sclerosis","volume":"12","author":"Harrington","year":"2023","journal-title":"Elife [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib10","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","article-title":"Cladribine (2-chlorodeoxyadenosine)","volume":"340","author":"Beutler","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2024.e00379_bib11","doi-asserted-by":"crossref","first-page":"11929","DOI":"10.1523\/JNEUROSCI.1860-14.2014","article-title":"An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex","volume":"34","author":"Zhang","year":"2014","journal-title":"J\u00a0Neurosci [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40262-018-0695-9","article-title":"The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis","volume":"58","author":"Hermann","year":"2019","journal-title":"Clin Pharmacokinet [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/acn3.414","article-title":"Effects of fumarates on inflammatory human astrocyte responses and oligodendrocyte differentiation","volume":"4","author":"Galloway","year":"2017","journal-title":"Ann Clin Transl Neurol [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib14","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.3390\/ijms23073615","article-title":"Effects mediated by dimethyl fumarate on in vitro oligodendrocytes: implications in multiple sclerosis","volume":"23","author":"Guerriero","year":"2022","journal-title":"Int J Mol Sci [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib15","first-page":"134","article-title":"Dimethyl fumarate induces metabolic crisie to suppress pancreatic carcinoma","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaut.2017.09.009","article-title":"Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis","volume":"86","author":"Diebold","year":"2018","journal-title":"J\u00a0Autoimmun [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tips.2017.11.002","article-title":"The pharmacokinetics of fumaric acid esters reveal their in vivo effects","volume":"39","author":"Mrowietz","year":"2018","journal-title":"Trends Pharmacol Sci [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jneuroim.2016.08.006","article-title":"Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments","volume":"299","author":"Peng","year":"2016","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.neurot.2024.e00379_bib19","article-title":"Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells","volume":"9","author":"Blewett","year":"2016","journal-title":"Sci Signal [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jneuroim.2015.04.006","article-title":"DMF, but not other fumarates, inhibits NF-\u03baB activity in vitro in an Nrf2-independent manner","volume":"283","author":"Gillard","year":"2015","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.neurot.2024.e00379_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/acn3.270","article-title":"Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis","volume":"3","author":"Michell-Robinson","year":"2016","journal-title":"Ann Clin Transl Neurol [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jneuroim.2006.04.016","article-title":"Effects of interferon-beta on oligodendroglial cells","volume":"177","author":"Heine","year":"2006","journal-title":"J\u00a0Neuroimmunol [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2990.2010.01095.x","article-title":"Interferon (IFN) beta treatment induces major histocompatibility complex (MHC) class I expression in the spinal cord and enhances axonal growth and motor function recovery following sciatic nerve crush in mice","volume":"36","author":"Zanon","year":"2010","journal-title":"Neuropathol Appl Neurobiol [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.diff.2022.10.004","article-title":"Interferon-beta induces major histocompatibility complex of class I (MHC-I) expression and a proinflammatory phenotype in cultivated human astrocytes","volume":"128","author":"Ignarro","year":"2022","journal-title":"Differentiation [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0165-5728(95)00072-A","article-title":"Interferon \u03b2-lb reduces Interferon \u03b3-induced antigen-presenting capacity of human glial and B cells","volume":"61","author":"Jiang","year":"1995","journal-title":"J\u00a0Neuroimmunol [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","article-title":"The clinical pharmacokinetics of cladribine","volume":"32","author":"Liliemark","year":"1997","journal-title":"Clin Pharmacokinet [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-5728(96)00128-2","article-title":"\u03b2-interferon regulates the immunomodulatory activity of neonatal rodent microglia","volume":"72","author":"Hall","year":"1997","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.neurot.2024.e00379_bib28","first-page":"213","article-title":"Interferon-\u03b2 inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines","volume":"30","author":"Garrison","year":"1996","journal-title":"J\u00a0Neuro Oncol [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0165-5728(96)00060-4","article-title":"Recombinant Interferon-\u03b2 blocks proliferation but enhances interleukin-10 secretion by activated human T-cells","volume":"67","author":"Rep","year":"1996","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.neurot.2024.e00379_bib30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1212\/WNL.49.2.385","article-title":"Interferon-\u03b2 interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes","volume":"49","author":"Pette","year":"1997","journal-title":"Neurology [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib31","doi-asserted-by":"crossref","first-page":"34677","DOI":"10.1074\/jbc.M110.164350","article-title":"Blocking interferon \u03b2 stimulates vascular smooth muscle cell proliferation and arteriogenesis","volume":"285","author":"Schirmer","year":"2010","journal-title":"J\u00a0Biol Chem [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0149-2918(97)80042-2","article-title":"Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis","volume":"19","author":"Munschauer","year":"1997","journal-title":"Clin Therapeut [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/1352458517740213","article-title":"Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells","volume":"25","author":"Mazzola","year":"2019","journal-title":"Mult Scler J [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1074-7613(03)00264-4","article-title":"Natural killer cells activated by MHC class ILow targets prime dendritic cells to induce protective CD8 T cell responses","volume":"19","author":"Mocikat","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.neurot.2024.e00379_bib35","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1084\/jem.182.5.1517","article-title":"Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma","volume":"182","author":"Lu","year":"1995","journal-title":"J\u00a0Exp Med [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0165-5728(89)90072-6","article-title":"Interferon-\u03b2 impairs induction of HLA-DR antigen expression in cultured adult human astrocytes","volume":"23","author":"Barna","year":"1989","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.neurot.2024.e00379_bib37","article-title":"Chemical and genetic control of IFN \u03b3-induced MHCII expression","volume":"19","author":"Wijdeven","year":"2018","journal-title":"EMBO Rep [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib38","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrn917","article-title":"Why does remyelination fail in multiple sclerosis?","author":"Franklin","year":"2002","journal-title":"Nat Rev Neurosci [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib39","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.65469","article-title":"Prolonging the integrated stress response enhances cns remyelination in an inflammatory environment","volume":"10","author":"Chen","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.neurot.2024.e00379_bib40","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.2353\/ajpath.2008.080449","article-title":"Enhanced integrated stress response promotes myelinating oligodendrocyte survival in response to interferon-\u03b3","volume":"173","author":"Lin","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.neurot.2024.e00379_bib41","first-page":"1","article-title":"Subcutaneous interferon b-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: analysis of PRISMS and SPECTRIMS trials","volume":"3","author":"Traboulsee","year":"2017","journal-title":"Mult Scler J - Exp Transl Clin [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1468-1331.1998.520187.x","article-title":"Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration","volume":"5","author":"Munafo","year":"1998","journal-title":"Eur J Neurol [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib43","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cei.13473","article-title":"Cladribine modifies functional properties of microglia","volume":"201","author":"J\u00f8rgensen","year":"2020","journal-title":"Clin Exp Immunol [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib44","article-title":"Effect of cladribine on neuronal apoptosis: new insight of in vitro study in multiple sclerosis therapy","volume":"10","author":"Ruggieri","year":"2020","journal-title":"Brain Sci [online]"},{"key":"10.1016\/j.neurot.2024.e00379_bib45","doi-asserted-by":"crossref","first-page":"102861","DOI":"10.1016\/j.msard.2021.102861","article-title":"A\u00a0pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers","volume":"51","author":"Edwards","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2024.e00379_bib46","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/jid.2010.416","article-title":"Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect?","volume":"131","author":"Garc\u00eda-Caballero","year":"2011","journal-title":"J\u00a0Invest Dermatol [online]"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924000655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747924000655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T21:11:31Z","timestamp":1727125891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747924000655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1878747924000655"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00379","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological modulation of inflammatory oligodendrocyte progenitor cells using three multiple sclerosis disease modifying therapies in vitro","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2024.e00379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00379"}}